NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF

- Researchers Demonstrate Immunomodulatory Effects of Laquinimod on
Disease Activity -

Contact: Elana Holzman    Teva Pharmaceutical       +972-(3)-926-7554
         Kevin Mannix     Industries Ltd.           +1-(215)-591-8912
                          Teva North America
Contact: Tomas Leanderson Active Biotech AB         +46-46-19-20-95
         Göran Forsberg   Active Biotech AB         +46-46-19-11-54


Jerusalem, Israel, Lund,  Sweden and Seattle,  Washington, April  28,
2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and  Active
Biotech (NASDAQ  OMX  NORDIC:  ACTI)  today  announced  results  from
several  new  clinical  and  preclinical  studies  providing  further
insight  on  the  immunomodulatory  mechanism  of  action  (MOA)   of
laquinimod, a novel oral once-daily compound being developed for  the
treatment of relapsing-remitting multiple sclerosis (RRMS). Four sets
of data  being  presented at  the  61st Annual  American  Academy  of
Neurology  Meeting   (AAN)  in   Seattle   stand  to   increase   the
understanding  of  how  laquinimod  may  reduce  multiple   sclerosis
activity and affect mechanisms related to disease pathology.

NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF LAQUINIMOD, AN ORAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Attachments